FY2025 Earnings Forecast for BDX Issued By Zacks Research

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at Zacks Research decreased their FY2025 earnings estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $14.36 per share for the year, down from their previous estimate of $14.39. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $4.21 EPS, Q4 2026 earnings at $4.46 EPS, FY2026 earnings at $15.49 EPS and FY2027 earnings at $16.66 EPS.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.42 EPS.

A number of other brokerages have also commented on BDX. Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $238.05 on Wednesday. The company has a market cap of $69.04 billion, a price-to-earnings ratio of 40.08, a PEG ratio of 1.72 and a beta of 0.39. The business has a 50 day moving average price of $227.31 and a 200 day moving average price of $232.79. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $248.42.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after acquiring an additional 673,568 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after acquiring an additional 460,440 shares during the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $108,243,000. Finally, The Manufacturers Life Insurance Company raised its position in Becton, Dickinson and Company by 62.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock valued at $266,974,000 after purchasing an additional 424,487 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 638 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the sale, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 over the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were given a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.75%. The ex-dividend date of this dividend was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.